Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Thyroid Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1442714
This article is part of the Research Topic Advances in precision medicine in the management of thyroid nodules and thyroid cancer View all 29 articles

Comparing therapeutic outcomes: radioactive iodine therapy versus non-radioactive iodine therapy in differentiated thyroid cancer

Provisionally accepted
Robert A. Tiuca Robert A. Tiuca 1Oana M. Tiuca Oana M. Tiuca 2Raluca M. Pop Raluca M. Pop 1*Ionela M. Pascanu Ionela M. Pascanu 1
  • 1 Department of Endocrinology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureş, Targu Mures, Romania
  • 2 Department of Dermatology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Targu Mures, Romania

The final, formatted version of the article will be published soon.

    significantly protected against incomplete biochemical control in the overall population (p = 0.019) and in patients with histological indolent DTC (p = 0.030). Predictive factors for incomplete biochemical control included male sex (p = 0.008) and incomplete structural control (p = 0.002) across all patients, regardless of the histological type.While RAI therapy has traditionally been used to manage DTC, our study found no significant difference in biochemical and structural responses between patients who received RAI therapy and those who did not. However, RAI therapy emerged as a protective factor against incomplete biochemical control, even in histological indolent DTC cases. These findings suggest that while RAI therapy may not be universally necessary, it could be beneficial in reducing the risk of biochemical recurrence in select patient subgroups, such as those with incomplete structural control or male patients. Thus, a personalized approach to RAI therapy, tailored to individual risk factors, may improve patient outcomes without overtreatment.RAI therapy can provide long-term benefits across all histological types of differentiated thyroid cancer (DTC). By lowering the likelihood of a biochemical incomplete response, it might effectively diminish the risk of cancer recurrence. Therefore, incorporating RAI therapy into the treatment plan for DTC patients may improve the overall prognosis and long-term survival rates.

    Keywords: Differentiated thyroid cancer, Radioactive iodine therapy, biochemical control, Therapy outcomes, personalized management

    Received: 02 Jun 2024; Accepted: 02 Sep 2024.

    Copyright: © 2024 Tiuca, Tiuca, Pop and Pascanu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Raluca M. Pop, Department of Endocrinology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureş, Targu Mures, Romania

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.